ArticleInternational ophthalmology2026
Formulation development and preclinical assessment of ethyl acetate fraction of Saraca asoca (EASA) flowers for cataract management.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCataract is the leading cause of reversible blindness globally. Current treatment options are limited to surgical intervention, highlighting the need for pharmacological alternatives. The primary objective of this study was to develop an ocular formulation containing the ethyl acetate fraction of Saraca asoca (EASA) flowers and to evaluate the anti-cataract activity using in vitro, ex vivo and in vivo models.
methodsThe EASA extract was characterized and analyzed by chromatographic techniques for the presence of phytoconstituents and the extract was formulated into an eye drop at 5 mg/mL. A comprehensive preclinical study evaluated the safety and efficacy of an ophthalmic formulation. Studies included in vitro antioxidant assays, in vitro irritation potential, ex vivo goat lens cataract model, in vivo ocular safety, in vivo diabetes, and UV-induced cataract models, affecting physiological enzymes and lens opacity.
resultsChromatographic analysis confirmed the presence of gallic acid, apigenin, and quercetin as key biomarkers from the EASA extract. The eye drop formulation produced a HET-CAM score of 0.5 (non-irritant) and the rabbit test showed no eye irritation up to 24 h. No abnormality or toxicity was observed after 28 days of ocular instillation. EASA exhibited significant antioxidant activity in DPPH, ABTS, FRAP assays and inhibited aldose reductase activity. Ex vivo studies of EASA demonstrated remarkable protection against lens opacification and in vivo treatment with EASA formulation preserved lens clarity compared to the negative control, while restoring endogenous antioxidants GSH, SOD and CAT to levels approaching those of normal controls.
conclusionDeveloped EASA eye drop formulation is non-irritant, ocularly safe, and displays potent antioxidant and aldose reductase inhibitory effects. EASA formulation significantly prevented and mitigated diabetes and UV-induced cataracts in preclinical models, supporting its potential as a non-invasive therapeutic option for cataract and ocular health management.
Indexed as
Identifiers
42470532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.